Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
The DOI matches its Crossref record; 17 of the 18 references it cites were found in a registry or an index.
Abstract
Six healthy young male volunteers at a contract research organization were enrolled in the first phase 1 clinical trial of TGN1412, a novel superagonist anti-CD28 monoclonal antibody that directly stimulates T cells. Within 90 minutes after receiving a single intravenous dose of the drug, all six volunteers had a systemic inflammatory response characterized by a rapid induction of proinflammatory cytokines and accompanied by headache, myalgias, nausea, diarrhea, erythema, vasodilatation, and hypotension. Within 12 to 16 hours after infusion, they became critically ill, with pulmonary infiltrates and lung injury, renal failure, and disseminated intravascular coagulation. Severe and unexpected depletion of lymphocytes and monocytes occurred within 24 hours after infusion. All six patients were transferred to the care of the authors at an intensive care unit at a public hospital, where they received intensive cardiopulmonary support (including dialysis), high-dose methylprednisolone, and an anti-interleukin-2 receptor antagonist antibody. Prolonged cardiovascular shock and acute respiratory distress syndrome developed in two patients, who required intensive organ support for 8 and 16 days. Despite evidence of the multiple cytokine-release syndrome, all six patients survived. Documentation of the clinical course occurring over the 30 days after infusion offers insight into the systemic inflammatory response syndrome in the absence of contaminating pathogens, endotoxin, or underlying disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Although the solid phase assay does not replicate in vivo presentation of TGN1412, which is not fully understood, it does induce substantial cytokine release equivalent to that reported in trial volunteers.”
From Severity of the TGN 1412 trial disaster cytokine storm correlated with IL‐2 release (2013) · cites this paper as [2]
Experimental — accuracy not yet measuredIn the citing paper
“In 2006, a life-threatening 'cytokine storm', not predicted by pre-clinical safety testing, rapidly occurred in all six healthy volunteers during the phase I clinical trial of the CD28 superagonist monoclonal antibody (mAb) TGN1412.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“One of the most striking features of the TGN1412-mediated 'cytokine storm' observed in humans was substantial TNF-a release within the first hour of infusion followed by dramatic increases in IFN-g, IL-2, IL-6, IL-8 and IL-10 plasma concentrations within 4 h (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“Concentrations of TNF-a measured by ELISA in culture supernatants collected 24 h after in vitro TGN1412 stimulation were also consistent with the peak concentrations reported in trial volunteers, with the considerable caveat that a comparison is being made between an in vitro system and an in vivo response.”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
In the citing paper
“However, despite similar in vitro expression kinetics for IFN-g following TGN1412 stimulation, the concentrations of IFN-g were far lower than TNF-a responses in vitro, and an order of magnitude lower than concentrations of IFN-g predicted from in vivo responses in trial participants (Suntharalingam et al., 2006).”
From Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4 + effector memory T‐cells (2010) · cites this paper as Suntharalingam et al., 2006
35 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“10.1073/pnas.0501997102”
Cited work 10.1073/pnas.0501997102 · retracted 2009-07-09 · notice 10.1073/pnas.0906977106 · this paper published 2006-09-07
Citations
Cites
1 retracted
Gon, Y., Wood, M. R., Kiosses, W. B., Jo, E., Sanna, M. G., Chun, J., & Rosen, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501997102 · Cited by 128
RetractedBone, R. C., Balk, R. A., Cerra, F. B., Dellinger, R. P., Fein, A. M., Knaus, W. A., Schein, R. M. H., & Sibbald, W. J. (1992) · Chest · doi:10.1378/chest.101.6.1644 · Cited by 13,198
Bernard, G. R., Artigas, A., Brigham, K. L., Carlet, J., Falke, K., Hudson, L., Lamy, M., Legall, J. R., Morris, A., & Spragg, R. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.149.3.7509706 · Cited by 6,746
Sepsis-Induced Apoptosis Causes Progressive Profound Depletion of B and CD4+ T Lymphocytes in Humans
Hotchkiss, R. S., Tinsley, K. W., Swanson, P. E., Schmieg, R. E., Hui, J. J., Chang, K. C., Osborne, D. F., Freeman, B. D., Cobb, J. P., Buchman, T. G., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.11.6952 · Cited by 934
Clinical risks for development of the acute respiratory distress syndrome.
Hudson, L. D., Milberg, J. A., Anardi, D., & Maunder, R. J. (1995) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.151.2.7842182 · Cited by 890
Brivet, F. G., Kleinknecht, D. J., Loirat, P., & Landais, P. J. M. (1996) · Critical Care Medicine · doi:10.1097/00003246-199602000-00003 · Cited by 879
Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., & Engert, A. (1999) · Blood · doi:10.1182/blood.v94.7.2217.419k02_2217_2224 · Cited by 657
Wing, M. G., Moreau, T., Greenwood, J., Smith, R. M., Hale, G., Isaacs, J., Waldmann, H., Lachmann, P. J., & Compston, A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119110 · Cited by 257
Beyersdorf, N., Gaupp, S., Balbach, K., Schmidt, J., Toyka, K. V., Lin, C.-H., Hanke, T., Hünig, T., Kerkau, T., & Gold, R. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20051060 · Cited by 203
Cited by
Items 1,601–1,700 of 2,162
Developability Assessment Workflows to De-Risk Biopharmaceutical Development
Zurdo, J., Arnell, A., Obrezanova, O., Smith, N., Gallagher, T. R. A., de la Cuesta, R. G., & Locwin, B. (2015) · CRC Press eBooks · doi:10.1201/b19023-13 · Cited by 3
Biomarkers in Discovery and Preclinical Phase During Drug Development
Lee, J. W. (2016) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-40793-7_5 · Cited by 2
A Global Perspective on First-in-Man Dose Selection: Oncology and Beyond
Zou, P., Lee, S., Li, M., Yu, L. X., & Sun, D. (2016) · Springer eBooks · doi:10.1007/978-3-319-39053-6_3 · Cited by 2
IPILIMUMAB IN THERAPY OF METASTATIC MELANOMA
Самойленко, И. В., Kharkevich, G. Y., & Demidov, L. V. (2016) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2016-10-84-92 · Cited by 2
Kurihara, C., Hoshi, J., SUZUKI, C., Suzuki, K., Kasai, H., Morishita, N., Sato, Y., Suhara, T., & Watanabe, H. (2016) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.47.219 · Cited by 2
Problematic, severe asthma in children: a new concept and how to manage it
Bush, A. (2010) · Acta medica Lituanica · doi:10.2478/v10140-010-0007-7 · Cited by 2
“Th e recent serious adverse events due to a cytokine storm with human monoclonals is a warning of the dangers of these approaches (84).”
BackgroundTranslational challenges of immunotoxicity assessments
Subramanyam, M., Lane, J. H., & Fikes, J. (2017) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2017.03.004 · Cited by 2
Signaling pathways in rheumatoid arthritis
Waldburger, J., & Firestein, G. S. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8238-4_9 · Cited by 2
“In a first-in-man clinical trial, the CD28 superagonist antibody TGN1412 produced a severe inflammatory reaction resulting in multi-organ failure [ 45 ].”
BackgroundDiversity of CD28null T Cells in the Elderly: A Glimpse in a Biological Adaptation of Aging
Griffin, P. C., Michel, J. J., & Vallejo, A. N. (2017) · Springer eBooks · doi:10.1007/978-3-319-64597-1_87-1 · Cited by 2
Iwata, Y., Harada, A., Kubo, C., Inoue, T., Tabo, M., & Mishima, M. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.05.125 · Cited by 2
Mechanistic ligand-receptor interaction model: operational model of agonism
Kim, H., & Lim, H. (2018) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2018.26.3.115 · Cited by 2
“Introduction In 2006, six healthy volunteers in the UK who participated in a phase 1 study on TGN1412, a humanized CD28 agonist, had severe multiorgan failure.[1] Because of this disaster, we recognized that a more appropriate approach to estimate the optimal initial dosing level is needed especially for drugs with ag…”
BackgroundShould We Design Clinical Trials Differently in the Era of Cancer Immunotherapy?
Lin, C. (2019) · Journal of Immunotherapy and Precision Oncology · doi:10.4103/jipo.jipo_5_19 · Cited by 3
CD8+ T Cell Biology in Cytokine Storm Syndromes
Sekine, T., Galgano, D., Casoni, G. P., Meeths, M., & Bryceson, Y. T. (2019) · Springer eBooks · doi:10.1007/978-3-030-22094-5_9 · Cited by 2
Biological Modulation of the Treg:Teff Ratio: From Immunosuppression to Immunoactivation
Yang, X., & Scott, M. D. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92038 · Cited by 2
Genetisch modifizierte regulatorische T-Zellen: Therapiekonzepte und ihr regulatorischer Rahmen
Sebe, A., Anliker, B., Rau, J., & Renner, M. (2020) · Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz · doi:10.1007/s00103-020-03230-8 · Cited by 4
A Non-Paternalistic Model of Research Ethics and Oversight
London, A. J. (2021) · Oxford University Press eBooks · doi:10.1093/oso/9780197534830.003.0007 · Cited by 2
Phase-I studies and first-in-human trials
Derhaschnig, U., & Jilma, B. (2010) · Springer eBooks · doi:10.1007/978-3-7091-0144-5_7 · Cited by 3
Advanced Approaches in Immunotherapy for the Treatment of Type 1 Diabetes Mellitus
Ceballos, B., Alexander, M., & Lakey, J. R. T. (2020) · EMJ Diabetes · doi:10.33590/emjdiabet/20-00062 · Cited by 3
Kim, S., Shukla, R. K., Kim, E., Cressman, S. G., Yu, H. J., Baek, A., Choi, H., Kim, A., Sharma, A., Wang, Z., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10061221 · Cited by 3
Cytokine storm mitigation for exogenous immune agonists
Kareva, I., & Gevertz, J. L. (2023) · Mathematics of Control Signals and Systems · doi:10.1007/s00498-023-00362-5 · Cited by 3
“One of the most notable therapy-induced instances of cytokine storm was the case of a Phase I clinical trial of monoclonal antibody TGN1412, which resulted in severe damage to the health of six volunteers that participated in the trial despite very carefully chosen initial doses (8); numerous additional reports of the…”
Mason, N. J., & DOW, S. W. (2023) · CABI eBooks · doi:10.1079/9781789245820.0008 · Cited by 2
Potential Malfeasant Cooption of Nanotechnology
Kosal, M. E. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0062-3_4 · Cited by 2
Optimising the Development of Antibodies as Treatment for Cancer
Carden, C. P., Arkenau, H., & Bono, J. S. D. (2010) · Springer eBooks · doi:10.1007/978-1-4419-7358-0_19 · Cited by 3
“1 mg/kg, all over the space of an hour in March 2006; all of them rapidly became extremely unwell [64].”
BackgroundOvercoming Cancer Tolerance with Immune Checkpoint Blockade
Clifton, G. T., Mittendorf, E. A., & Peoples, G. E. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_6 · Cited by 2
Tolerance in Organ Transplantation
Boucault, L., Bézie, S., Ossart, J., & Guillonneau, C. (2016) · InTech eBooks · doi:10.5772/62653 · Cited by 3
“[121] Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al.”
BackgroundMicroencapsulated Cells for Cancer Therapy
del Burgo, L. S., Ciriza, J., Hernández, R. M., Orive, G., & Pedraz, J. L. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6364-5_21 · Cited by 2
Immunophenotyping in Drug Development
Kimzey, A. L., Piche, M.-S., Wood, M., Weir, A. B., & Lansita, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64236-8 · Cited by 4
Mécanismes d’action et toxicités potentielles des anticorps monoclonaux
Bejan‐Angoulvant, T., & Alexandre, J. (2019) · médecine/sciences · doi:10.1051/medsci/2019208 · Cited by 11
Fontenot, A. P., & Simonian, P. L. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-3383-5.00013-0 · Cited by 4
Doubovetzky, M., Ataman‐Önal, Y., Chousterman, B. G., Feroldi, E., Garçon, N., Grillet, M.-H., Kramer, D., Laurent, S., Lewis, D. J. M., Luna, E., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.10.015 · Cited by 3
Chen, M. L., Peng, N., Liu, X. Y., et al. (2021) · PubMed · doi:10.3760/cma.j.issn.0253-2727.2021.03.007 · Cited by 2
“[20] Suntharalingam G, Perry MR, Ward S, et al.”
BackgroundGhosh, D., Sugimoto, H., Lee, J. Y., & Qian, M. G. (2021) · Analytical Chemistry · doi:10.1021/acs.analchem.1c00146 · Cited by 2
Xenobiotic‐Induced Inflammation: Pathogenesis and Mediators
Clements, P. (2009) · Wiley eBooks · doi:10.1002/9780470744307.gat167 · Cited by 2
Erdman, A. R., Nickas, J., & Brown, B. (2011) · Wiley eBooks · doi:10.1002/9780470975053.ch12 · Cited by 2
van der Laan, J. W., Herberts, C. A., Jones, D., Thorpe, S. J., Stebbings, R., & Thorpe, R. (2014) · Wiley eBooks · doi:10.1002/9783527676965.ch9 · Cited by 2
Ethical and practical issues in phase 1 trials in healthy volunteers
Senn, S. J. (2014) · Wiley eBooks · doi:10.1002/9781118763070.ch4 · Cited by 2
Stirred Tank Reactors for Cell Culture Technology
Pangarkar, V. G. (2014) · Wiley eBooks · doi:10.1002/9781118807774.ch7b · Cited by 2
Estimation of Human Starting Dose for Phase I Clinical Programs
Buckley, L. A., Garhyan, P., Ponce, R. A., & Roberts, S. (2010) · Wiley eBooks · doi:10.1002/9780470613191.ch10 · Cited by 2
Hafner, A. M. (2012) · Repository for Publications and Research Data (ETH Zurich) · doi:10.3929/ethz-a-007326128 · Cited by 2
Bernton, E. W. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse173 · Cited by 2
Basic Science for the Clinician 46
Sigal, L. H. (2007) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0b013e318156d215 · Cited by 2
Evaluating the evidence base in pharmacovigilance decision making
Tang, A. (2010) · OpenGrey (Institut de l'Information Scientifique et Technique) · Cited by 2
Lipid-Mediated in vivo Delivery of Small Interfering RNAs
MacLachlan, I. (2008) · Royal Society of Chemistry eBooks · doi:10.1039/9781847558275-00241 · Cited by 2
Transgenic Rice for the Production of Recombinant Pharmaceutical Proteins
Yang, D., Ou, J., Shi, J., et al. (2018) · doi:10.1002/9781118801512.ch11 · Cited by 2
Epstein-Barr virus promotes T cell dysregulation in a humanized mouse model of multiple sclerosisPreprint
Allanach, J. R., Fettig, N. M., Hardman, B. K., Fan, V., Rosen, A. R., Goldberg, E. J., Morse, Z. J., Shanina, I., Vorobeychik, G., Osborne, L. C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.23.481716 · Cited by 2
Attenuation of Immune Suppression to Complement Glioma Immunotherapy
Field, C. S. (2016) · doi:10.26686/wgtn.17013761.v1 · Cited by 2
Intratumoral administration of mRNA-1273 vaccine delays melanoma growth in micePreprint
Boehm, D. T., Landreth, K. M., Sen-Kilic, E., Lee, K. S., Misra, B., Bobbala, S. K. R., Damron, F. H., & Liu, T. W. B. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.06.592840 · Cited by 2
“27 28 Alternative indirect routes of boosting cytokine and chemokine responses are an attractive approach due to safety.”
BackgroundStadtmüller, A., Grampp, R., Schnitter, F., Becker, F., Nuriyeva, K., Langenhorst, D., Metka, L., Günther, K., Gladow, N., Hofmann, U., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.28.685145 · Cited by 1
“All twelve pigs survived the antibody infusion and exhibited no signs or symptoms of an allergic reaction or even a CRS.”
InfluentialClinical efficacy and safety of biosimilar epoetin: focus on epoetin zeta
Mikhail, A. I., & Brown, C. S. (2015) · Biosimilars · doi:10.2147/bs.s50456 · Cited by 1
Changes in Research and Development of Medicinal Products since the Paediatric Regulation
Ceci, A., Catapano, M., Manfredi, C., Wong, I. C. K., Orlu, M., Meneguz, A., Baiardi, P., Pasqua, O. E. D., Iolascon, A., Scarpa, M., et al. (2011) · InTech eBooks · doi:10.5772/28797 · Cited by 2
“The 20th century history of drug research and regulation shows that dramatic tragedies such as sulfanilamide (Wax, 1995), thalidomide (Choonara & Rieder, 2002) and TGN 1412 (Suntharalingam et al., 2006) cases facilitated the passage of stronger laws.”
BackgroundLimitations of Pathology and Animal Models
Neef, N. (2017) · Wiley eBooks · doi:10.1002/9781118755174.ch8 · Cited by 2
Abdul, M. I. M. (2017) · Tropical Journal of Pharmaceutical Research · doi:10.4314/tjpr.v16i4.24 · Cited by 1
Rational Autonomy and Decision-Making Capacity
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0008 · Cited by 4
Rationality and Decisional Autonomy
Pugh, J. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780198858584.003.0003 · Cited by 1
Risk Management and Communication: Building Trust and Credibility With the Public
Vahle, J. L., Bhat, V. S., & Wood, C. E. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00022-1 · Cited by 5
Ethics of Preanesthesia Mandatory Laboratory Testing
Hunter, J., Jackson, S. H., & Norman, G. A. V. (2024) · Anesthesiology Clinics · doi:10.1016/j.anclin.2024.01.002 · Cited by 1
FDA’s Project Optimus: The “Paradigm-Shifting” Initiative for Oncology Drug Development
Mi, G., & Lin, J. (2024) · ICSA book series in statistics · doi:10.1007/978-3-031-67110-4_3 · Cited by 5
Falkenberg, C., Sørensen, D. B., Hansen, C. H., Toft, M., & Hansen, A. K. (2024) · Laboratory Animals · doi:10.1177/00236772241279058 · Cited by 1
“6 The anti-CD28 immune blocker caused a nearly fatal cytokine storm in humans subjected to a clinical trial, 10 which in contrast to SPF mice was also observed when retested in wildlings.”
Preclinical Safety Assessment: General and Genetic Toxicology
LeRoy, B. E., & Blomme, E. A. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11881-4.00003-x · Cited by 1
Novel Drug Strategies in Kidney Transplantation
Chediak, A. E., Levea, S.-L. L., & Wojciechowski, D. (2025) · Current Transplantation Reports · doi:10.1007/s40472-025-00479-3 · Cited by 1
Rastegari, A., & Mohebbi, F. (2025) · Transplant Immunology · doi:10.1016/j.trim.2025.102328 · Cited by 2
Pirillo, E., Freenor, F., V, Wamba, B. E. N., Bhatnagar, S., Mondal, T., & Tushir‐Singh, J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110962 · Cited by 3
“Based on clinical findings with the immune-stimulating CD28 agonist TGN1412 antibody (3), targeting CD226 (DNAM-1) with agonists is not a preferred therapeutic approach due to severe and potentially fatal immune over-stimulation (3).”
Draper, I. H., Selke, W., Ritmeester-Loy, S. A., Harsh, F. M., Annesley, C., Summers, C. N., Gardner, R. A., Kim, W., & Smith, S. E. P. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013023 · Cited by 2
“44 Additionally, CD28 costimulatory CAR T cells produce more toxicities in patients than 41BB costimulatory T cells, 45 supporting the idea that CD28 signaling may contribute to CRS. Structurally, CD28 signaling occurs on ligand recognition, but only when Ca2+ elevations due to local TCR activation…”
Friedrich, V. D., Neier, K. E., Müller, K., Fogal, B., Loncová, Z., Rade, M., Shoaib, M., Koehl, U., Hoyt, K., Pande, P., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1603716 · Cited by 1
Advancing ICOS agonism in solid tumors: lessons from INDUCE-1
Habibzadeh, P., & Davar, D. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013991 · Cited by 2
Hiner, C. R., Mueller, A. L., Garforth, S., Bravo, M. S., Hur, H. B., Voss, A., Zheng, J. H., Kandpal, M., Low, S., Almo, S. C., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkaf329 · Cited by 2
“64,65 We previously reported that NLV-FLAG IST without a co-stimulatory domain could expand NLV-specific CD8 þ T cells in vivo using a humanized NOD scid gamma mouse model with no exogenous cytokine support, likely by utilizing autonomous human IL-2 or other cytokines secreted by human T cells.”
Drug Development in Non-Oncogene-Addicted Non-Small Cell Lung Cancer
Cruz, P., Boixareu, C., Silva, D., Ting, J., Sena, R. H. R., Pang, S. A., Mullings, S., & Minchom, A. (2026) · Cancers · doi:10.3390/cancers18050880 · Cited by 1
“Phase I trials focus primarily on safety rather than efficacy, recognising that extensive pre-clinical studies may still incorrectly predict side effects and clinically effective doses [153,154].”
Trispecific antibodies in cancer therapy: Mechanisms, clinical progress and future directions
Liu, X., Fan, X., Wang, Y., Wang, L., Lu, D., Wang, Y., Meng, X., Fan, L., Zhu, W., Liu, X., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116503 · Cited by 3
Game of microbes: a wildling’s guide
Bruno, P., & Rosshart, S. P. (2026) · Trends in Microbiology · doi:10.1016/j.tim.2025.12.017 · Cited by 1
Fardel, O., Mahfoudhi, E., Launay, L., Moreau, A., Denizot, C., Malnoë, D., & Parmentier, Y. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2665791 · Cited by 2
“Common positive controls include alem-tuzumab, muromonab-CD3, and TGN1412 (acting as a CD28 superagonist), all of which have been associated with high CRS incidence in clinical settings [90,91].”
Tremblay, S., Abaigar, A., Allton, P., Sardinha, D., Patel, S. J., Shah, K., Maynard, J., & Otulana, B. (2026) · Transplantation · doi:10.1097/tp.0000000000005701 · Cited by 2
“13,14 However, unlike therali-zumab, VEL-101 is, by design, a CD28 antagonist as it (1) targets a nonactivating CD28 epitope and (2) is a mono-valent antibody fragment, thereby preventing cross-linking CD28 receptors that could result in CD28 activation.”
Budhavaram, N. K., Duffy, K. H., Abouzeid, A. H., Bharadwaj, R., Shrestha, N., Echeverri, E. S., Mitchener, C., & Subramony, J. A. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115893 · Cited by 2
Structural mechanism of biased activation of T cell receptor by a high-affinity antibody
Li, X., Huang, B., Shao, E., Zhu, Y., Yang, D., Chen, Y., Gao, W., Lu, Z., Lu, F., Zhang, A., et al. (2026) · Vita · doi:10.15302/vita.2026.03.0021 · Cited by 2
Antibody binding geometry and affinity control inhibitory hFcγRIIB receptor signaling
Fisher, H., Sutton, E. J., Oldham, R. J., et al. (2026) · Immunity · doi:10.1016/j.immuni.2026.05.019 · Cited by 1
Deuse, T., & Schrepfer, S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102888 · Cited by 2
Araki, T., Naraoka, H., Asakawa, Y., Usui, T., Kakiuchi, D., Kurashige, S., Shinozawa, T., Nakamura, K., Noda, T., Nishikawa, S., et al. (2026) · NAM journal. · doi:10.1016/j.namjnl.2026.100114 · Cited by 1
“A well-known case in which severe adverse events occurred in the first-in-human trial despite no significant toxicity observed in animal studies is the clinical trial of the anti-CD28 antibody TGN1412 (Suntharalingam et al., 2006).”
Safety Aspects of Biologics: Lessons Learnt from Monoclonal Antibodies
Schneider, C. K., & Löwer, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-29018-6_16 · Cited by 1
Cellular and Molecular Markers of Outcome in Septic Shock
Monserrat, J., de, R., Daz, D., Snchez, M.-A., Reyes, E., Prieto, A., & de Mo, M. L. (2012) · InTech eBooks · doi:10.5772/29704 · Cited by 1
“Recently, it has been reported that the stimulation of CD28 by a monoclonal antibody in healthy volunteers is followed by severe multiple cytokine-release syndrome (Suntharalingam et al. 2006).”
BackgroundPhase I Studies and First-In-Human Trials
Derhaschnig, U., & Jilma, B. (2016) · Springer eBooks · doi:10.1007/978-3-319-27347-1_7 · Cited by 2
“This antibody was a recombinantly expressed, humanized superagonist anti-CD28 antibody that stimulates and expands T cells independently of the ligation of the T-cell receptor [ 10 ].”
BackgroundEarly De-risking Strategy for Novel Biotherapeutics
Narayanan, P. K., Ponce, R. A., & Hinkle, B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00003-4 · Cited by 2
Phase I studies: the role of publicly funded academic-healthcare partnerships
Brendish, N. J., Gbesemete, D. F., de Graaf, H., et al. (2015) · BMJ · doi:10.1136/bmj.h3889 · Cited by 1
Médiateurs de l’inflammation au cours du sepsis
Cavaillon, J. (2011) · Springer eBooks · doi:10.1007/978-2-8178-0064-6_2 · Cited by 1
Targeting Immunological Synapse: New Horizons in Immunotherapy for Cancer
Chmielowski, B., & Ribas, A. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-087-8_48 · Cited by 1
Immuno Oncology: What have the Last 3 Decades Brought?
Margaret, A. (2015) · MOJ Immunology · doi:10.15406/moji.2015.02.00047
“The phase I trial of TGN1412 or CD28 Super MAB, a Mab with agonist activity specific to CD28, caused life-threatening immune inflammatory reactions in the small number of healthy volunteers to whom it was given [13].”
BackgroundThe fiendish behavior of TNF can be counteracted by microRNA
Cavaillon, J. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505380 · Cited by 1
Biothérapies : des médicaments comme les autres ?
Paintaud, G., Tonelli, D., Postaire, E., Amalric, F., Bassompierre, F., Becquemont, L., Cartron, G., Cellier, D., Dagher, G., Demerens, T., et al. (2007) · Therapies · doi:10.2515/therapie:2007040 · Cited by 1
“L’exemple du TGN1412 (de la société TeGenero), qui a entraîné des effets indésirables graves chez des sujets sains lors d’une étude de phase I,[2] a été discuté.”
Mentoring in the ethics of clinical research: An ongoing need
Markman, M. M. (2007) · Current Oncology Reports · doi:10.1007/s11912-007-0027-y · Cited by 1
Schmolz, M. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.7.935 · Cited by 1
Maximum group sizes for simultaneous testing in high potential risk scenarios
Coolen, F. P. A. (2013) · Proceedings of the Institution of Mechanical Engineers Part O Journal of Risk and Reliability · doi:10.1177/1748006x13489483 · Cited by 1
“A famous case where simultaneous testing during a phase-1 trial went horribly wrong, and which attracted much media attention, is the 2006 trial of the anti-CD28 monoclonal antibody TGN1412.(5) This double-blind, randomized trial involved eight healthy young male volunteers, two of whom were administered a placebo.”
BackgroundInfluentialThe Role of Biological Agents in Immunotherapy
Abdulkareem, I. H. (2013) · Journal of Postgenomics Drug & Biomarker Development · doi:10.4172/2153-0769.1000116 · Cited by 1
“There was also recurrent fever, respiratory difficulty, cardiovascular shock, renal failure, hospital-acquired infections, peripheral ischaemia, disseminated intravascular coagulation and generalised skin desquamation [11].”
BackgroundEthical Considerations in Cancer Immunotherapy
Markman, M. M. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_27 · Cited by 1
Gelfond, J., Heitman, E., Pollock, B. H., et al. (2012) · Statistics in Medicine · doi:10.1002/sim.5578 · Cited by 1
“We even argued that a sample size of six could be too large [2].”
BackgroundOverview of hypersensitivity to cancer therapies
O’Neil, B. H. (2010) · Community Oncology · doi:10.1016/s1548-5315(11)70383-7 · Cited by 1
Knowledge-Driven, Data-Assisted Integrative Pathway Analytics
Reddy, P. S., Murray, S., & Liu, W. (2013) · IGI Global eBooks · doi:10.4018/978-1-4666-3604-0.ch009 · Cited by 1
Clinical trial designs for more rapid proof-of-principle and approval
Borad, M. J., & Hoff, D. D. V. (2008) · Elsevier eBooks · doi:10.1016/b978-012369448-5.50006-9 · Cited by 3
The Role of Contract Research Organizations (CROs) in Imaging for the Drug Development Process
den Daas, I., van Iersel, T. M., & Wemer, J. (2012) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814317740_0022 · Cited by 1
Noninfectious Disease Vaccines
El-Turabi, A., & Bachmann, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00040-7 · Cited by 3
Castro-Rojas, C. M., Alloway, R. R., Woodle, E. S., & Hildeman, D. A. (2019) · Current Transplantation Reports · doi:10.1007/s40472-019-0225-1 · Cited by 1
Antilymphocyte Globulin, Monoclonal Antibodies, and Fusion Proteins
Chambers, E. T., & Kirk, A. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-53186-3.00019-x · Cited by 1
Of mice, men and microbes: the impact of the microbiome on immune responses
Pisetsky, D. S. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-216936 · Cited by 1
“15 Importantly, in the study by Rosshart et al , while the conventional laboratory mice showed the expected Treg cell induction with CD28SA treatment at day 4, the wildling mice did not increase this population but rather showed high levels of proinflammatory cytokines as well as interleukin…”
Metadata
- Authors
- Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N.
- Affiliations
- Hammersmith Hospital (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-09-07
- Volume
- 355
- Issue
- 10
- Pages
- 1018-1028
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2141989396
- Cited by
- 2,164
- References
- 18
- Citations by year
- 2026: 57 · 2025: 73 · 2024: 95 · 2023: 79 · 2022: 79 · 2021: 120 · 2020: 141 · 2019: 94 · 2018: 102 · 2017: 97 · 2016: 117 · 2015: 122 · 2014: 118 · 2013: 120 · 2012: 114
- FWCI
- 80.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- cytokine release syndrome, TGN1412, anti-CD28 monoclonal antibody, systemic inflammatory response syndrome, inflammatory cytokines, acute respiratory distress syndrome, disseminated intravascular coagulation, renal failure, drug-induced immunotoxicity
- MeSH terms
- Adult, Antibodies, Monoclonal, C-Reactive Protein, Critical Care, Double-Blind Method, Hemodynamics, Humans, Hypotension, Infusions, Intravenous, Leukopenia, Male, Multiple Organ Failure, Thrombocytopenia, Cytokines, CD28 Antigens, Disease Progression, APACHE, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.